JAK2 c.250_251del ;(p.M84Vfs*6)

Variant ID: 9-5029803-AAT-A

NM_004972.3(JAK2):c.250_251del;(p.M84Vfs*6)

This variant was identified in 1 publication

View GRCh38 version.




Publications:


Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.

Therapeutic Advances In Medical Oncology
Yang, Hong H; Liu, Zhimin Z; Wang, Yufang Y; Li, Jun J; Li, Ruiqian R; Wang, Qilin Q; Hu, Chen C; Jiang, Haiyang H; Wu, Hongyi H; Song, Lele L; Bai, Yu Y
Publication Date: 2020

Variant appearance in text: JAK2: 250_251del; M84Vfs*6
PubMed Link: 33240400
Variant Present in the following documents:
  • Main text
  • 10.1177_1758835920970845.pdf
View BVdb publication page